MINNEAPOLIS, June 17 /PRNewswire-FirstCall/ —
ProUroCare Medical, Inc. (OTC Bulletin Board: PUMD), a provider of
proprietary imaging products, today announced that it has closed on
a $885,000 private placement of debt
financing. The funding was provided by a small group of
existing investors closely aligned with the company.
The proceeds from the financing will be used to fund
manufacturing and marketing scale-up activities, expand the
company’s existing intellectual property portfolio and form a
scientific advisory board. A portion of the funding will also
be used to pay existing debt obligations and for general corporate
purposes.
“This additional funding brings the total amount raised by the
company since 2007 to more than $9.3
million,” said CEO Rick
Carlson. “We are very pleased by the support that we
continue to receive from investors for the ProUroScan™
prostate imaging system and the market opportunities that exist for
this technology. Our immediate focus is to ensure the
successful processing of our de novo filing and the
resulting FDA clearance for commercialization.”
About ProUroCare Medical, Inc.
ProUroCare Medical, Inc. is a publicly traded company engaged in
the business of developing innovative medical imaging products. The
company’s current focus is the ProUroScan prostate imaging system,
which is used to document abnormalities of the prostate detected by
a Digital Rectal Exam (DRE). Based in Minneapolis, Minn., ProUroCare is quoted
on the OTCBB.
Safe Harbor Statement
This news release contains
‘/>”/>
SOURCE